List of works - Emanuela Salvatorelli

4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.

scientific article published in June 2009

Anthracycline cardiotoxicity

scientific article published on 02 June 2011

Anthracycline cardiotoxicity

scientific article published on 01 January 2008

Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.

scientific article published on January 2010

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

scientific article (publication date: June 2004)

Cardiotoxicity of antitumor drugs

scientific article published on 01 April 2008

Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.

scientific article published on 22 April 2011

Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.

scientific article published on 19 January 2006

Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies

scientific article published on 29 November 2006

Doxorubicin degradation in cardiomyocytes

scientific article published on 27 April 2007

Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox.

scientific article published on December 2014

Managing anthracycline-induced cardiotoxicity: beginning with the end in mind

scientific article

Matters of the Heart: The Case of TNF -Targeting Drugs

scientific article published on 01 April 2011

Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies

scientific article published on 13 April 2006

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin

scientific article published on 15 February 2012

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin

scientific article published on 15 February 2012

Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis

scientific article published on 12 September 2012

Pharmacological foundations of cardio-oncology.

scientific article

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.

scientific article published in March 2004

Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship

scientific article published on 16 June 2014

The concomitant management of cancer therapy and cardiac therapy

scientific article

The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.

scientific article published on 28 November 2012

List of works by Emanuela Salvatorelli

4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.

Anthracycline cardiotoxicity

Anthracycline cardiotoxicity

Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

Cardiotoxicity of antitumor drugs

Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.

Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.

Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies

Doxorubicin degradation in cardiomyocytes

Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox.

Managing anthracycline-induced cardiotoxicity: beginning with the end in mind

Matters of the Heart: The Case of TNF -Targeting Drugs

Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin

Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis

Pharmacological foundations of cardio-oncology.

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.

Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship

The concomitant management of cancer therapy and cardiac therapy

The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.